Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973710 | 1.00 | MAOB (0.53) | MAOBPAMKMT2AMEN1ALDH1A1 | |
| SCHEMBL9790488 | 0.83 | MAOB (0.53) | MAOBPAMKMT2AMEN1HTT | |
| SCHEMBL9790495 | 0.83 | MAOB (0.53) | MAOBPAMKMT2AMEN1HTT | |
| SCHEMBL9439949 | 0.81 | MAOB (0.57) | MAOBPAMKMT2AMEN1ALDH1A1 | |
| SCHEMBL1582564 | 0.80 | MAOB (0.61) | MAOBPAMKMT2AMEN1ALDH1A1 | |
| SCHEMBL1694508 | 0.80 | MAOB (0.61) | MAOBPAMKMT2AMEN1ALDH1A1 | |
| SCHEMBL10619606 | 0.80 | MAOB (0.61) | MAOBPAMKMT2AMEN1ALDH1A1 | |
| SCHEMBL9318255 | 0.78 | MAOB (0.58) | MAOBPAMKMT2AMEN1ALDH1A1 | |
| SCHEMBL8261373 | 0.77 | MAOB (0.57) | MAOBPAMKMT2AMAOAMMP1 | |
| SCHEMBL2453746 | 0.77 | MAOB (0.57) | MAOBPAMKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | MAOB 963/4885PAM 3826/4885KMT2A 4048/4885 |
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | MAOB 1629/4885PAM 942/4885KMT2A 4301/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | MAOB 977/4885PAM 3946/4885KMT2A 3255/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | MAOB 2375/4885PAM 1184/4885KMT2A 4597/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | MAOB 2432/4885PAM 344/4885KMT2A 1072/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | MAOB 2375/4885PAM 1184/4885KMT2A 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.